{
  "nctId": "NCT02079246",
  "briefTitle": "Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease",
  "officialTitle": "An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease",
  "protocolDocument": {
    "nctId": "NCT02079246",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2015-06-16",
    "uploadDate": "2018-06-14T08:09",
    "size": 515712,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02079246/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 1463,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2014-04-07",
    "completionDate": "2017-07-06",
    "primaryCompletionDate": "2017-07-06",
    "firstSubmitDate": "2014-02-28",
    "firstPostDate": "2014-03-05"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* the patient has completed Visit 7 (Completion Visit) in the lead-in double-blind, placebo controlled clinical studies 14861A/NCT01955161 or 14862A/NCT02006641\n\nFor patients in the OLEX-MEM:\n\n* The patient has completed Visit 6 (Week 28) of the OLEX.\n* The patient, according to the judgement of the investigator, requires initiation of treatment with memantine as per local label/SmPC/treatment guidelines.\n\nExclusion Criteria:\n\n* The patient has a moderate or severe ongoing adverse event from the lead-in study considered a potential safety risk by the investigator.\n* The patient has experienced seizures before Completion Visit in the lead-in study.\n* The patient has evidence of clinically significant disease.\n* The patient's donepezil treatment is likely to be interrupted or discontinued during the study.\n* The patient is receiving therapy with another acetylcholinesterase inhibitors (AChEI).\n\nOther protocol-defined inclusion and exclusion criteria may apply.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "50 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX",
        "description": "A TEAE is an adverse event that starts or increases in intensity after the date of Baseline II.",
        "timeFrame": "Baseline II (start of OLEX, week 0) to end of OLEX (week 28)"
      },
      {
        "measure": "Number of TEAEs in the OLEX-MEM",
        "description": "A TEAE is an adverse event that starts or increases in intensity after the date of Baseline III (start of OLEX-MEM).",
        "timeFrame": "From Baseline III (start of OLEX-MEM, Week 28) to end of OLEX-MEM (Week 52)"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Cognition",
        "description": "Change from Baseline II to Week 28 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) total score. The ADAS-cog is a 11-item neuropsychological test that assess the severity of cognitive impairment. The items determine the patient's orientation, memory, language, and praxis. Total score of the 11 items range from 0 to 70 (lower score indicates lower cognitive impairment).",
        "timeFrame": "Baseline II (start of OLEX, Week 0) to Week 28"
      },
      {
        "measure": "Clinical Global Impression Score",
        "description": "Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score at Week 28. The ADCS-CGIC is a semi-structured interview to assess clinically relevant changes in patients with AD. The items determine cognition, behavior, social and daily functioning. Severity at baseline is rated on a 7-point scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). The clinically relevant change from baseline is rated on a 7-point scale from 1 (marked improvement) to 7 (marked worsening).",
        "timeFrame": "Week 28"
      },
      {
        "measure": "Change in Daily Functioning",
        "description": "Change from Baseline II to Week 28 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score. The ADCS-ADL23 is a 23-item clinician-rated inventory to assess activities of daily living (conducted with a caregiver or informant). Each item comprises a series of hierarchical sub-questions, ranging from the highest level of independent performance to a complete loss for each activity. Total score of the 23 items ranges from 0 to 78 (higher score indicates lower disability).",
        "timeFrame": "Baseline II (start of OLEX, Week 0) to Week 28"
      },
      {
        "measure": "Change in Behavioural Disturbance",
        "description": "Change from Baseline II to Week 28 in Neuropsychiatric Inventory (NPI) total score. The NPI is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is rated for frequency (a 4-point scale from 1 \\[occasionally\\] to 4 \\[very frequent\\]) and severity (a 3-point scale from 1 \\[mild\\] to 3 \\[marked\\]). The total NPI score is the frequency ratings multiplied by the severity ratings and ranges from 0 to 144 (higher score indicates worse outcome).",
        "timeFrame": "Baseline II (start of OLEX, Week 0) to Week 28"
      },
      {
        "measure": "Change in Cognitive Aspects of Mental Function",
        "description": "Change from Baseline II to Week 28 in Mini Mental State Examination (MMSE). The MMSE is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit).",
        "timeFrame": "Baseline II (start of OLEX, Week 0) to Week 28"
      },
      {
        "measure": "Change in Cognitive Aspects of Mental Function",
        "description": "Change from Baseline III to Week 52 in Mini Mental State Examination (MMSE). The MMSE is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit).",
        "timeFrame": "Baseline III (start of OLEX-MEM, Week 28) to Week 52"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 6,
      "otherCount": 0,
      "totalCount": 8
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:39.589Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}